Sign Up Now
Get instant access to over 1 million+ study documents
OR
Already registered? click here to login
By creating your account, you agree to our terms of service, privacy policy and student honor code.
Asthma and Stepwise Management
Asthma is a common disorder that affects around 1 in 13 Americans today (Asthma facts and figures, 2018). Although there is no cure for asthma, the condition can be managed effectively using various methods, including most especially a stepwise approach. The purpose of this paper is to provide a description of long-term control and quick relief treatment options for asthma sufferers and side effects such interventions can cause. In addition, an explanation concerning the stepwise approach to asthma treatment and management and how stepwise management assists health care providers and patients in gaining and maintaining control of the disease is followed by a summary of the research and key findings concerning asthma treatment and management in the conclusion.
Long-term control and quick relief treatment options for asthma patients, as well as the impact these drugs might have on patients
The long-term treatment options for asthma are intended to reduce the inflammation of the airway and reduce the frequency and severity of asthma symptoms while quick-relief treatment options such as inhaled short-acting beta2-agonists are intended to relieve the symptoms of asthma as they occur (Asthma treatment, 2018). According to the National Heart, Lung, and Blood Institute, “Inhaled corticosteroids are the preferred medicine for long-term control of asthma. They're the most effective option for long-term relief of the inflammation and swelling that makes airways sensitive to...
5). In addition, other pharmacological interventions that are commonly used for long-term asthma treatment include Cromolyn in the form of a nebulizer and Omalizumab (anti-IgE) (Asthma symptoms, 2018).
The stepwise approach to asthma treatment and management
While a number of different strategies are available for asthma treatment and management, Arcangelo and Peterson (2013) maintain that the stepwise approach provides the optimal clinical outcomes. A general stepwise approach to asthma treatment and management for patients aged 12 years and over is set forth in Table 1 below.
Table 1
Stepwise approach to asthma treatment and management
Step 1
Step 2
Step 3
Step 4
Step 5
Step 6
Use of a short-acting
beta-agonist
(e.g., albuterol prn)
If used more than 2
days per week
(other than for
exercise) consider
inadequate control
and the need to
step up treatment.
Low-dose
inhaled steroid or leukotriene
blocker or
cromolyn
Low-dose
inhaled steroid +
long-acting beta
agonist or
Medium-dose
inhaled steroid
Medium-dose
inhaled steroid +
long-acting beta
agonist
High-dose…
References
Arcangelo, V. P., & Peterson, A. M. (Eds.). (2013). Pharmacotherapeutics for advanced practice: A practical approach. Ambler, PA: Lippincott Williams & Wilkins.
Asthma facts and figures. (2018). Asthma and Allergy Foundation of America. Retrieved from http://www.aafa.org/page/asthma-facts.aspx.
Asthma treatment. (2018). National Heart, Lung, and Blood Institute. Retrieved from https://www.nhlbi.nih.gov/node/3894.
Stepwise approach to managing asthma. (2018). Asthma Initiative for Healthy Lungs. Retrieved from http://getasthmahelp.org/documents/gist-stepwise-approach.pdf
Asthma Management Asthma is a scare and terrible affliction that affects a lot of people to varying degrees. However, long-term control options do exist and they are executed in an orderly fashion by doctors and other medical professionals in coordination with their patients. Indeed, there is what is known as a "stepwise" approach to asthma management. This report shall discuss that and it will also discuss how the stepwise management assists
Asthma and Stepwise Management Long-term control and quick relief treatment, and the effect on patients Health care comprises of giving treatment for acute asthmatic incidents and management of persistent symptoms, which includes exercise-provoked and nocturnal asthmatic symptoms. Pharmacological controls entail the application of management mechanisms: inhaled corticosteroids, theophylline, long-acting bronchodilators (anticholinergics and beta-agonists), leukotriene transformers and the more current tactics for example the utilization of Ige, that is, anti-immunoglobulin E. antibodies (Omalizumab),
Long-term and Quick Relief Treatment Options Bronchial asthma is a chronic inflammation of someone’s bronchial tubes (Szefler, Holguin, & Wechsler, 2017). Inflammation of respiratory airways leads to narrowing and swelling of the bronchi resulting in difficult breathing. Some of the symptoms of asthma are coughing and wheezing, shortness of breath, and chest pain/tightness (Szefler, Holguin, & Wechsler, 2017). There are various treatments for bronchial inflammation. Some are long-term, and some are
Improving Health for Children With Asthma Childhood Asthma Improving Health Outcomes for Inner-City Children with Asthma Improving Health Outcomes for Inner-City Children with Asthma Centers for Disease Control and Prevention (CDC) engages in active surveillance of childhood asthma because it is prevalent, contributes significantly to childhood morbidity, and imposes an economic burden on families (CDC, 2012). The main recommendations for diagnosing and managing asthma by the National Heart, Lung, and Blood Institute (NHLBI) and
Pathopharmacological Foundation Asthma Analyze the Pathophysiology of Asthma The complex chronic inflammatory disease known as asthma, involves several inflammatory cells, more than a hundred distinct mediators of inflammation, and various inflammatory outcomes, such as plasma exudation, broncho-constriction, activation of the sensory nerves, and hyper-secretion of mucus. Mast cells contribute immensely to mediation of acute symptoms of asthma; on the other hand, T-helper 2 cells, eosinophils, and macrophages are factors that cause airway hyper
Pathopharmacological Foundation Asthma Analyze the Pathophysiology of Asthma The complex chronic inflammatory disease known as asthma, involves several inflammatory cells, more than a hundred distinct mediators of inflammation, and various inflammatory outcomes, such as plasma exudation, broncho-constriction, activation of the sensory nerves, and hyper-secretion of mucus. Mast cells contribute immensely to mediation of acute symptoms of asthma; on the other hand, T-helper 2 cells, eosinophils, and macrophages are factors that cause airway hyper